Ivabradine
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Ivabradine: From Chronic Heart Failure/Angina to Hypertrichosis
One-Sentence Summary
Ivabradine is a selective HCN (If, "funny current") channel blocker that slows sinoatrial node firing, used clinically for chronic heart failure and stable angina. The TxGNN model predicts it may be effective for Hypertrichosis (disease), but this prediction is currently supported by 0 clinical trials and 0 publications, and the evidence pack itself notes no known mechanistic link between HCN-channel inhibition and hair growth regulation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (drugbank original_indications field empty) |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.79% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed original-indication and formal MOA fields are not populated in this evidence pack. However, the pack's own repurposing rationale describes ivabradine as a selective HCN channel blocker acting at the sinoatrial node to reduce heart rate, used for chronic heart failure and stable angina.
There is no established biological pathway connecting sinoatrial HCN-channel inhibition to hair follicle growth regulation (e.g., Wnt/β-catenin signaling or androgen receptor pathways implicated in hypertrichosis). The evidence pack explicitly states this candidate arises purely from graph-embedding similarity in the TxGNN model, without direct or indirect clinical or mechanistic support.
The same pattern holds across all six predicted indications in this pack — hypertrichosis, Ambras syndrome, periodontal malformation syndrome, Dandy-Walker malformation, hair shaft abnormality, and nephrogenic syndrome of inappropriate antidiuresis. Each rationale text independently flags the lack of a plausible mechanistic connection to HCN-channel pharmacology, and the periodontal-disease literature retrieved (rank 3) consists of general periodontology reviews that never mention ivabradine, indicating keyword-matching noise rather than drug-specific evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Norway Market Information
Ivabradine is not marketed in Norway under this evidence pack (market_status: 未上市, 0 total licenses). No authorization records are available to list.
Safety Considerations
Please refer to the package insert for safety information.
(Note: the underlying evidence pack flags TFDA warnings/contraindications data as a Blocking data gap (DG001), meaning a formal safety screen (S1) cannot currently be performed for this candidate.)
Conclusion and Next Steps
Decision: Hold
Rationale: All six TxGNN-predicted indications for ivabradine are rated L5 (model prediction only), with zero supporting clinical trials and no drug-specific literature. The evidence pack's own mechanistic rationale for the top-ranked prediction (hypertrichosis) explicitly states there is no known biological link to ivabradine's HCN-channel mechanism. Combined with the drug's unmarketed status in Norway and a Blocking-severity gap in TFDA safety labeling data, there is no basis to advance this candidate beyond the discovery stage.
To proceed, the following is needed:
- TFDA/regulatory label data (warnings, contraindications) — currently Blocking gap (DG001)
- Confirmed mechanism of action data from DrugBank (DG002)
- Any preclinical or mechanistic study directly linking HCN-channel modulation to hair follicle biology or the other predicted phenotypes
- Re-evaluation if future TxGNN model updates surface higher-confidence, mechanistically plausible indications for this compound
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.